CAR therapies
Humanigen's Lenzilumab With CAR T-Cell Therapy Improves Response in Lymphoma
The firm will initiate a Phase II registrational study of lenzilumab with all commercially available CD19 CAR T-cell therapies in diffuse large B-cell lymphoma.
Eden BioCell Doses First Patient in Phase I CAR T-Cell Study
The Ziopharm Oncology, TriArm Therapeutics joint venture is evaluating the autologous therapy for patients with relapsed CD19-positive leukemias and lymphomas.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
FDA Accepts IND for Arcellx's Multiple Myeloma Cell Therapy
The firm plans to begin a Phase I trial of its autologous, controllable T-cell cell therapy, ACLX-001, for multiple myeloma patients in the second half of 2021.
Gilead Submits Application With FDA to Expand Tecartus Use to Acute Lymphoblastic Lymphoma
In a supplemental application, Gilead company Kite submitted data on its CAR T-cell therapy from the Zuma-3 trial in relapsed or refractory B-cell precursor ALL.